Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;27(6):831-5.
doi: 10.1007/s10552-016-0757-y. Epub 2016 May 4.

A prospective study of autoantibodies to Ezrin and pancreatic cancer risk

Yaqiong Sun  1   2 , Jie Wu  1 , Hui Cai  1 , Shuyang Wang  1 , Qiaolan Liu  1   3 , William J Blot  1   4 , Xiao Ou Shu  1 , Qiuyin Cai  5
Affiliations

A prospective study of autoantibodies to Ezrin and pancreatic cancer risk

Yaqiong Sun et al. Cancer Causes Control. 2016 Jun.

Abstract

Purpose: No biomarker is available for pancreatic cancer early detection, but a small prospective European study involving 16 cases and 32 controls raised the possibility that anti-Ezrin autoantibodies may be associated with risk of pancreatic cancer. We aimed to validate this finding in a case-control study nested within a prospective study in the USA.

Methods: Levels of anti-Ezrin autoantibodies were examined using ELISA in pre-diagnostic plasma samples of 73 cases and 145 matched controls. Paired t test and paired signed rank tests were used to determine the difference between two groups, and conditional logistic regression was used to evaluate the association between anti-Ezrin autoantibody levels and risk of developing pancreatic cancer.

Results: No association was found between levels of anti-Ezrin plasma autoantibodies and subsequent risk of developing pancreatic cancer.

Conclusion: Anti-Ezrin autoantibodies did not appear to be useful as a plasma biomarker for early detection of pancreatic cancer.

Keywords: Autoantibodies; Ezrin; Pancreatic cancer risk; Prospective study.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
    1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute; Bethesda, MD: 2015. http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
    1. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10(5):201–204. - PubMed
    1. Meng Y, Lu Z, Yu S, Zhang Q, Ma Y, Chen J. Ezrin promotes invasion and metastasis of pancreatic cancer cells. J Transl Med. 2010;8:61. - PMC - PubMed
    1. Capello M, Cappello P, Linty FC, et al. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J Hematol Oncol. 2013;6:67. - PMC - PubMed

Publication types

LinkOut - more resources